Loading
A phase 1/2 trial of Cyclophosphamide in ovarian cancer, run by Beijing Biotech, now recruiting.
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 is a phase 1/2 interventional study registered as NCT07617753 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: Dual-target CAR-NK cell product, Cyclophosphamide, supportive. Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies. No results are recorded here; the registry entry is the source.